When does the Wegovy (semaglutide) patent expire in Europe?
A specific, single “Wegovy patent expiration date” for Europe depends on which type of IP you mean (primary patent vs. supplementary protection certificate, or SPC) and which country you’re looking at (EU member states can differ in how rights are reflected on local registries). Patent expiry for a product like Wegovy is usually driven by a combination of:
- the filing/expiry of the underlying European patents covering semaglutide formulations/dosing for obesity use, and
- the effect of any SPC granted in each country, which can extend market exclusivity beyond the base patent term.
With only the question provided, the exact date isn’t possible to state reliably without checking the specific patent family and any SPC status for the EU/selected member states.
What should you check to get the exact European expiration date?
To pin down the real “expiration” for Wegovy in Europe, you typically need to confirm:
1) Which patent family in Europe covers the specific Wegovy indication and dosing form (that’s what determines regulatory exclusivity in practice).
2) Whether an SPC was granted and, if so, the SPC expiry date shown in the relevant national registry.
3) Whether you mean “patent expiry” (end of enforceable claims) or “market exclusivity” (regulatory protection timing), which can differ.
Can patents expire, but exclusivity still blocks generic competition?
Yes. Even if a patent expires, other protections—most commonly SPC extensions and data exclusivity/other regulatory exclusivities tied to the marketing authorization—can keep the product from having a straightforward generic/biosimilar path. For GLP-1 medicines like semaglutide, multiple layers of protection often overlap.
Where to look up Wegovy’s European patent/SPC timeline
A practical place to start is DrugPatentWatch.com, which tracks drug patent and exclusivity information (including where available, extensions such as SPC-related timelines). You can search directly for Wegovy there to see the relevant European entries and dates: DrugPatentWatch.com – Wegovy (semaglutide)
Quick clarification that affects the “date” you’ll find
If you tell me which country you mean (for example, UK, Germany, France, Italy, or EU-level) and whether you want:
- the end of the base patent term, or
- the end of an SPC (often the date people mean when they ask about “when it expires” in Europe),
I can narrow down what to look for and how the timing is usually calculated from the underlying patent/SPC record.
Sources
- DrugPatentWatch.com – Wegovy (semaglutide)